At the conclusion of this activity, participants will be able to:

1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.

2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.

3. Facilitate discussions with patients and caregivers regarding RCC treatment options.

This educational series is supported by independent educational grants from:

Astellas

AstraZeneca

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck

Pfizer, Inc

Sanofi Genzyme

UroGen Pharma, Inc.

CME Available: https://auau.auanet.org/node/29851